InfoBionic has assembled a Board of Directors with the necessary industry and practical experience required to successfully steer a cutting-edge medical technology firm.
Carl Berke, PhD
Founding Director, Mass Medical Angels (MA2)
Carl is a founding director of Mass Medical Angels and has been an active private equity investor as a member of Angel Healthcare Investors LLC. He is also a Partner at the Partners HealthCare Innovation Fund in Boston, investing in new biomedical technologies emerging from Massachusetts General Hospital and Brigham & Womens Hospital. His career spans 25 years in the practice and management of innovation to bringing new technologies from lab to market. Carl holds 6 US patents. Previously, he served as a Partner at Integral/Analysis Group, a management consultancy focused on innovation and growth strategy.
Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technology.
Jeremy Ruskin, MD
Chair of Scientific Advisory Board, Board Observer & Co-Founder
Dr. Ruskin is a world-renowned cardiologist and electrophysiologist. He is Founder and Director of the Cardiac Arrhythmia Service at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Ruskin received his undergraduate degree from Tufts University and his medical degree from Harvard Medical School. He completed his residency in Internal Medicine at Beth Israel Hospital in Boston and his fellowship in Cardiovascular Disease at the Massachusetts General Hospital. He received his training in clinical and experimental cardiac electrophysiology at the USPHS Hospital in Staten Island, New York under the mentorship of Dr. Anthony Damato.
Dr. Ruskin has trained more than 110 fellows in the subspecialty of cardiac arrhythmias over the past 38 years, many of whom are in leadership positions at academic centers throughout the world. In addition, Dr Ruskin is a much sought after speaker at medical conferences and has authored more than 450 original scientific publications, chapters, reviews, and monographs. Dr. Ruskin’s major research interests include: the mechanisms and management of atrial fibrillation; new antiarrhythmic drugs and innovative non-pharmacologic approaches to the treatment of atrial fibrillation; the mechanisms and prevention of ventricular arrhythmias and sudden cardiac death; the role of arrhythmia control devices in the prevention of sudden cardiac death; the proarrhythmic effects of cardiac and non-cardiac drugs and cardiac safety issues in new drug and device development. In 1995, Dr. Ruskin founded the Annual International Atrial Fibrillation Symposium which he has directed since its inception and is the largest and longest running free-standing academic meeting on atrial fibrillation worldwide. Dr. Ruskin also maintains an active regional, national and international referral practice in the field of cardiac arrhythmias and electrophysiology and is recognized annually in Best Doctors in Boston and Best Doctors in America. He is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology and the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award.
CEO and Founder, lifeIMAGE
Hamid Tabatabaie is CEO and founder of lifeIMAGE, the most utilized cloud-based service for exchange of diagnostic imaging information. During his 30-year career in health information technology Hamid has served as the chief executive of 4 successful startups. For the past fifteen years, he has been at the forefront of innovation in medical imaging informatics. Prior to lifeIMAGE, he led AMICAS, a pioneer in use of the web to automate the processes and the business of diagnostic imaging. Following a personal experience as a caregiver frustrated with the inability to share medical records across various healthcare settings, he founded lifeIMAGE to develop a better way for physicians to share patients’ imaging records.
Now, 9 million records containing 2 billion images have been exchanged on lifeIMAGE. Many of the nation’s renowned hospitals and academic medical centers use the network to expedite care, triage referrals, and avoid duplication of unnecessary imaging exams. The network is simultaneously used to share medical images and associated reports with patients.
Chairman of the Board, InfoBionic; SVP and Managing Director, Safeguard Scientifics
Al Wiegman is Senior Vice President and Managing Director at Safeguard Scientifics (NYSE:SFE), which provides capital to technology-driven businesses in healthcare, financial services and digital media. Al brings more than 15 years of venture capital experience to Safeguard, possessing a successful track record of transactions across the technology and healthcare sectors. Al is currently a board member for Safeguard’s partner companies Aktana, Inc., Aventura, Inc., InfoBionic, Inc. (Chairman) and Zipnosis, Inc.
Prior to joining Safeguard, Al was a General Partner at HLM Venture Partners, a leading venture capital firm, with offices in Boston and San Francisco. At HLM, Al directly participated in 30 early- and growth-stage transactions across the technology and healthcare sectors, and was integrally involved in some notable exits including Madison Dearborn Partners, LLC’s acquisition of Fieldglass, Inc. and Hologic, Inc.’s acquisition of Interlace Medical. Al was also on the board of directors for other HLM portfolio companies including Soteira Inc., Linkwell Health, Inc., Spinal Kinetics, Inc., and Transcend Medical, Inc.
Al began his career as a Senior Financial Analyst at Fleet Bank of New York. He received an M.B.A. from Babson College and a B.A in Economics from Hobart College.
Managing Director, Excel Venture Management
Caleb has nearly 20 years of operating, startup, and financing experience in life science and healthcare companies. He plays an instrumental role in sourcing and structuring deals and works closely with portfolio companies to form strategic partnerships and to develop commercialization and marketing strategies. He currently (or formerly) represents Excel as a Board Director or Observer at Aventura, InfoBionic, Molecular Templates, ShapeUp, Saladax Biomedical, and MedVentive (sold to McKesson).
Prior to joining Excel, Caleb was a Principal at Biotechonomy, where he financed and managed several entrepreneurial ventures, including Synthetic Genomics, where he was also the Director of Finance, BioTrove (sold to Life Technologies), Biocius (sold to Agilent Technologies), and Xcellerex (sold to GE).
Prior to becoming a venture capitalist, Caleb was an award winning sales and marketing executive at medical device and diagnostics companies. He received his M.B.A. from Babson College, magna cum laude, where he was a Babson Fellow in the Center for Technology Enterprise. He received a B.A. in Biology with a minor in Economics from Colby College.
Are you ready to have afrom the status quo?
See how MoMe® Kardia is transforming arrhythmia detection management to bring a vital change to physicians and their patients.
Learn More About MoMe® Kardia for Practices
Talk to our team to discover how the MoMe® Kardia system is optimizing clinical and real-world utility for the users that need it most – physicians and their patients.